Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene
about
Vaccinia recombinant virus expressing the rabies virus glycoprotein: safety and efficacy trials in Canadian wildlife.CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic VirusesThe evolution of poxvirus vaccinesInduction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virusRabies Control and Treatment: From Prophylaxis to Strategies with Curative PotentialNovel vaccines to human rabiesProtection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein geneVaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicityImmune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein.Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteinsIdentification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.Persistence of genetic variants of the arctic fox strain of Rabies virus in southern Ontario.Prophylaxis of human hydrophobia in South KoreaExpression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection.Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trialsNew approaches to the prevention and eradication of rabies.Immunogenicity studies in carnivores using a rabies virus construct with a site-directed deletion in the phosphoprotein.Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice.Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoproteinComparison of representative strains of infectious hematopoietic necrosis virus by serological neutralization and cross-protection assaysSpatio-temporal Use of Oral Rabies Vaccines in Fox Rabies Elimination Programmes in Europe.Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice.Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein.The use of an E1-deleted, replication-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus.Effect of Corticosteroids on RVNA production of a patient with acute disseminated encephalomyelitis following rabies vaccination as well as administration of HRIG.Microparticles for oral delivery of vaccines.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrierA new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoproteinSickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N proteinPosttranslational side chain modification of a viral epitope results in diminished recognition by specific T cellsStructural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.Identification of an immunodominant epitope within the phosphoprotein of rabies virus that is recognized by both class I- and class II-restricted T cells.Synthesis, cellular location, and immunogenicity of bovine herpesvirus 1 glycoproteins gI and gIII expressed by recombinant vaccinia virusIsolation and characterization of neutralizing monoclonal antibodies to vaccinia virusVaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.Lyssaviruses.The ascension of wildlife rabies: a cause for public health concern or intervention?
P2860
Q24535640-83FFF9AE-CAB9-4534-8407-1ED09C2ED974Q26766798-81B93F3D-5C77-40FE-93E6-252D2B767E6CQ26995905-84BD88C9-5183-4B24-9F1F-C509BAE879BDQ27486585-08A3C666-4116-4CF0-B7FD-4EF2C5677A97Q28076429-BCE22801-AB10-4C0B-8D74-F0497929ADD1Q33507253-F1501410-9DDF-47B2-83B8-D7E547F72EA8Q33829701-E0543280-96CD-4903-A276-E1ADEF35BB0FQ33834391-A58270BB-DD9E-40F0-A506-1430FCB3814AQ34080569-0EDE9364-D624-431C-AB18-9C4C97D0A1BBQ34106038-6584151C-C518-40A7-AC68-29811DDAA902Q34162769-5EEF9981-9AD0-47D3-ABE8-863FEF11D76DQ34248621-B3BB3F8D-D7F9-49C7-8BEB-CE3F67E85F87Q34303983-E7D1ED50-8730-420B-AB18-326EEF183AF9Q34340404-8C3503AB-34FD-488A-B4FC-8CCDE8468B29Q34380312-DBDE57AC-BEB9-4149-9216-352691AC1FC3Q34671806-BEA18738-E24E-4F60-8260-0333DCD3D920Q35194187-44ADF5BB-CE66-45F9-AE12-D3620833B2ADQ35224835-473F94D4-52DA-4D8A-86CC-CACCCD3C5CF0Q35270981-5C395730-C1C0-4DA5-B282-9BB3B5B2AC7FQ35596022-4C2D5B8E-215C-4C4F-9CDC-DE3F9C54398DQ35691858-BB6A57BC-DE97-4D2D-B8BD-9BCE1BC4F73BQ35747805-47752CB5-F625-45C5-BA99-0731649ABA1DQ35837415-B936CF89-BDDE-42B3-95D9-08C9AEAE53B9Q35865836-A74A0831-8E76-4481-A03E-2E46FEBFB63EQ35883003-3A549086-8574-40D6-877D-5B750F553032Q35886459-0EAA3D78-4E2F-465D-8DB6-0B2787E72F11Q36316809-3721E905-ABF4-4A63-BF62-059D4AD97EF2Q36391900-F2F4E079-FF8B-4056-ACF2-A7D05C5AFC89Q36474203-BA4874B2-6EFD-4FF2-8693-C64B003A8006Q36559952-5B262FB3-EF65-4799-876F-B07E8B15C972Q36667958-F7C0C7BF-795E-4F1C-85D1-FD2B08E651ACQ36696504-801836E9-B312-469A-A2D4-5A5B21A9535DQ36698658-9EFDA95C-72A2-4547-908D-270F23F81FC2Q36812254-43025A39-CBF2-49CC-B22C-2ECF198670E3Q36820442-FDBECBE0-36F4-48F2-BA16-5CDFE0A19698Q36827447-DCE51273-A16D-4629-B655-046FF7B51592Q36852967-657E0471-FD40-4E35-8452-DD55FDBBAC3BQ36952733-C6CD7821-D80A-4F26-AF8C-BCACA527BE27Q37011499-C328B4B0-2853-435A-9B2B-B339F41F3260Q37062495-C0F6210C-05BD-491D-8F50-77E231869677
P2860
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene
description
1984 nî lūn-bûn
@nan
1984 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1984 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
name
Protection from rabies by a va ...... rabies virus glycoprotein gene
@ast
Protection from rabies by a va ...... rabies virus glycoprotein gene
@en
Protection from rabies by a va ...... rabies virus glycoprotein gene
@nl
type
label
Protection from rabies by a va ...... rabies virus glycoprotein gene
@ast
Protection from rabies by a va ...... rabies virus glycoprotein gene
@en
Protection from rabies by a va ...... rabies virus glycoprotein gene
@nl
prefLabel
Protection from rabies by a va ...... rabies virus glycoprotein gene
@ast
Protection from rabies by a va ...... rabies virus glycoprotein gene
@en
Protection from rabies by a va ...... rabies virus glycoprotein gene
@nl
P2093
P2860
P356
P1476
Protection from rabies by a va ...... rabies virus glycoprotein gene
@en
P2093
B Dietzschold
J P Lecocq
K J Reagan
P J Curtis
R I Macfarlan
T J Wiktor
W H Wunner
P2860
P304
P356
10.1073/PNAS.81.22.7194
P407
P577
1984-11-01T00:00:00Z